GT Biopharma, Inc. (GTBP) vs Traws Pharma, Inc. (TRAW)

A side-by-side comparison of GT Biopharma, Inc. and Traws Pharma, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — GTBP vs TRAW

growth of $100 · dividends reinvested · last 10y
GTBP -100.0% (-69.0%/yr)TRAW -100.0% (-64.2%/yr)TRAW compounded faster over this window
050100Start $10020182020202220242026$0$0
GTBP TRAW

GTBP vs TRAW: by the numbers

  • •GTBP is the larger company ($8M vs $8M market cap).
  • •TRAW is profitable (328.67% net margin) while GTBP runs a net loss (0.00%).

Metrics side by side

Valuation

MetricGTBPTRAW
P/B ratio2.25N/A

Profitability

MetricGTBPTRAW
Gross margin0.00%100.00%
Operating margin0.00%-640.68%
Net margin0.00%328.67%
ROE-618.74%N/A
ROIC-457.75%N/A

Growth (annualized)

MetricGTBPTRAW
Revenue CAGR (5Y)N/A64.60%
Total return CAGR (5Y)-73.13%-64.14%

Frequently asked

Is GTBP or TRAW more profitable?
TRAW runs the higher net margin — GTBP at 0.00% versus TRAW at 328.67%.
How have GTBP and TRAW total returns compared?
Over the past 10 years, GTBP delivered -68.76% and TRAW delivered -64.35% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.